Spring 2001
Page 1 to 8 of 8 |
REGENERATIVE MEDICINE promising answers in the face of an ageing population By Dr Doros Platika Spring 2001
As the population ages, the scientific and medical communities are working to solve the challenges this changing demographic will place on society. Companies involved in the promising field of regenerative medicine are now on the cutting edge as it strives to promote longevity without disability.

Read More

Protein therapeutics – new ladders up the fruit tree By Dr Richard AG Smith Spring 2001
Therapeutic proteins are often regarded as too technologically demanding, too costly, too restricted in routes or duration of administration or – in an era of massive opportunity provided by high throughput screening, combinatorial chemistry and genomics – simply passé. This article explores how fundamental advances (such as definition of the human proteome and protein combinatorics) as well as incremental steps forward (such as improvements in production methods) are rapidly expanding therapeutic uses for the biology’s most important molecules.

Read More

Pharmaceutical industry R&D partnering strategies By Riccardo Pigliucci Drug Discovery Spring 2001
With a sustained rate of more than 250 R&D partnering deals each year many valuable lessons are being learned. Although there is no exact ‘formula for success’ there are many ‘success factors’ that can be utilised to reduce the risk of failure.

Read More

Modelling and simulation in drug development, promise and reality By Dr Mark Sale Spring 2001
Modelling and simulation in drug development is not new. What is new is the
vision for moving from a descriptive role (what happened) to a predictive and
therefore decision making role. While seemingly attractive, important hurdles,
both scientific and practical, must be overcome.

Read More

Increasing the chances of lead discovery By Sandra Fox, MBA, Dr Helen Wang, Dr Lynne Sopchak and Dr Richard Khoury Spring 2001
For HTS laboratories worldwide, the mission is to supply therapeutic groups – in the shortest time possible – with high quality hits and leads that will become drug candidates. Mounting pressure to screen more targets against more compounds while providing more information per screen has HTS directors seeking improvements to existing technologies as well as innovative new approaches and tools.

Read More

Implementation or algorithm? By Dr Christopher Hogue Spring 2001
Recently the value of bioinformatics has been questioned. The value can be proven but are there enough qualified and professionally trained people who know how to build good bioinformatics tools?

Read More

e-R&D – the net@work By Dr Alpheus Bingham and Dr Neil Bodick Spring 2001
It is difficult to understand how the continuing growth of large monolithic Research & Development organisations can sustain the industry. With the economies of scale providing diminishing returns we examine the promise of e-R&D and explore the potential in networks.

Read More

Biologically relevant chemistry By Dr Stephen A. Hill Spring 2001
A large proportion of R&D expenditure relates to the investigation of compounds which ultimately fail to reach the market as useful medicines. We discuss why early drug discovery – using high throughput, automated in vitro and in silico methods, must become the primary testing ground for novel compounds – not clinical development.

Read More

Spring 2001
Page 1 to 8 of 8 |